Mini-dose GnRH-a long versus short protocol in patients ≥35 years old undergoing in vitro fertilization

References

• Baird DT, Collins J, Evers LH, et al. Fertility and ageing. Hum Reprod Update 2005;11:261–76
   PubMed Web of Science ®Google Scholar
• Szewczuk E. Age-related infertility: a tale of two technologies. Sociol Health Illness 2012;34:429–43
   PubMedGoogle Scholar
• Assisted reproductive technology in the United States: 2001 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology registry. Fertil Steril 2007;87:1253–66
   Google Scholar
• Marinakis G, Nikolaou D. National survey of the current management of infertility in women aged 40 and over in the UK. J Obstet Gynaecol 2012;32:375–8
   Google Scholar
• Sunderam S, Chang J, Flowers L, et al. Assisted reproductive technology surveillance-United States, 2006. MMWR Surveill Summ 2009;58:1–25
   PubMedGoogle Scholar
• Maheshwari A, Gibreel A, Siristatidis CS, et al. Gonadotropin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev 2011;8:CD006919
   Google Scholar
• Macklon NS. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev 2006;27:170–207
   PubMed Web of Science ®Google Scholar
• Pu D, Wu J, Liu J. Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF. Hum Reprod 2011;26:2742–9
   PubMed Web of Science ®Google Scholar
• Sbracia M, Farina A, Poverini R, et al. Short versus long gonadotropin-releasing hormone analogue suppression protocols for superovulation in patients ≥40 years old undergoing intra-cytoplasmic sperm injection. Fertil Steril 2005;84:644–8
   PubMed Web of Science ®Google Scholar
• Sbracia M, Colabianchi J, Giallonardo A, et al. Cetrorelix protocol versus gonadotropin-releasing hormone analog suppression long protocol for superovulation in intra-cytoplasmic sperm injection patients older than 40. Fertil Steril 2009;91:1842–7
   PubMed Web of Science ®Google Scholar
• Pandian Z, McTavish AR, Aucott L, et al. Interventions for ‘poor responders' to controlled ovarian hyper stimulation (COH) in invitro fertilization (IVF). Cochrane Database Syst Rev 2010;1:CD004379
   Google Scholar
• Geng L, Li W, Li X, et al. Controlled ovarian hyper-stimulation interventions in infertile women aged 40 years or older undergoing in vitro fertilization. Int J Gynecol Obstet 2009;106:193–7
   PubMed Web of Science ®Google Scholar
• San Roman GA, Surrey ES, Judd HL, et al. A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization. Fertil Steril 1992;58:744–9
   Google Scholar
• Coccia ME, Rizzello F. Ovarian Reserve. Anna New York Acad Sci 2008;1127:27–30
   PubMedGoogle Scholar
• Prapas Y, Petousis S, Dagklis T, et al. GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial. Eur J ObstetGynecol Reprod Biol 2013;166:43–6
   PubMed Web of Science ®Google Scholar
• DiLuigi AJ, Nulsen JC. Effects of gonadotropin-releasing hormone agonists and antagonists on luteal function. Curr Opin Obstet Gynecol 2007;19:258–65
   PubMed Web of Science ®Google Scholar
• Surrey ES. Management of the poor responder: the role of GnRH agonists and antagonists. J Assist Reprod Genet 2007;24:613–9
   PubMed Web of Science ®Google Scholar
• Janssens RM, Lambalk CB, Vermeiden JP, et al. Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study. Hum Reprod 2000;15:2333–40
   PubMed Web of Science ®Google Scholar
• Li Y, Yang D, Zhang Q. Clinical outcome of one-third-dose depot triptorelin is the same as half-dose depot triptorelin in the long protocol of controlled ovarian stimulation. JHum Reprod Sci 2012;5:14–9
   Google Scholar
• Ku SY, Choi YS, Byung J, et al. A preliminary study on reduced dose (33 or 25 μg) gonadotropin-releasing hormone agonist long protocol for multi-follicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels under going in vitro fertilization-embryo transfer. Gynecol Endocrinol 2005;21:227–31
   PubMed Web of Science ®Google Scholar
• Chatillon-Boissier K, Genod A, Denis-Belicard E, et al. Prospective randomized study of long versus short agonist protocol with poor responder patients during in vitro fertilization. Gynecol Obstet Fertil 2012;40:652–7
   Google Scholar
• Rao CV. Multiple novel roles of luteinizing hormone. Fertil Steril 2001;76:1097–100
   Google Scholar
• Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 2000;15:1003–8
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bungum L, Bungum M, et al. Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation. Hum Reprod 2002;17:2016–21
   PubMed Web of Science ®Google Scholar
• Strowitzki T, Germeyer A, Popovici R, et al. The human endometrium as a fertility-determining factor. Hum Reprod Update 2006;12:617–30
   PubMed Web of Science ®Google Scholar
• Ma WG. Estrogen is a critical determinant that specifies the duration of the window of uterine receptivity for implantation. Proc Natl Acad Sci 2003;100:2963–8
   PubMed Web of Science ®Google Scholar
• Bosch E, Labarta E, Crespo J, et al. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod 2010;25:2092–2100
   PubMed Web of Science ®Google Scholar
• Huang R, Fang C, Xu S, et al. Premature progesterone rise negatively correlated with live birth rate in IVF cycles with GnRH agonist: an analysis of 2566 cycles. Fertil Steril 2012;98:664–70
   PubMed Web of Science ®Google Scholar
• Van Vaerenbergh I, Fatemi HM, Blockeel C, et al. Progesterone rise on HCG day in GnRH antagonist/rFSH stimulated cycles affects endometrial gene expression. ReprodBioMed Online 2011;22:263–71
   PubMed Web of Science ®Google Scholar
• Wu Z, Li R, Ma Y, et al. Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles. Reprod BioMed Online 2012;24:511–20
   PubMed Web of Science ®Google Scholar